Vistagen Therapeutics Inc (VTGN) Implied Volatility Current

Tracking VTGN implied volatility helps you identify when options premiums on Vistagen Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Vistagen Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when VTGN IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Vistagen Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For VTGN, tracking metrics like VTGN IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on VTGN signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders.

The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where VTGN implied volatility sits today versus where it has been. Our scanner ranks Vistagen Therapeutics Inc implied volatility against its historical range, surfaces extremes in VTGN IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Vistagen Therapeutics Inc IV is rich or cheap — measure it, then act on it.